Heat therapy could zap thyroid nodules without surgery
NCT ID NCT05189808
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether radiofrequency ablation (RFA) can safely shrink thyroid nodules that are not clearly cancerous. RFA uses a tiny needle to deliver heat directly to the nodule. Researchers will review medical records from 50 adults to see how much the nodules shrink and if any complications occur.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Radiofrequency ablation (a procedure using heat from electrical currents to shrink nodules)
- What this could lead to
- If successful, this could confirm that radiofrequency ablation is a safe and effective way to shrink thyroid nodules without surgery.
- What could go wrong
- This is a small observational study (50 people) that only reviews existing data, not a controlled trial. The results may not apply to everyone, and risks like voice changes or bleeding exist.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 50 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Aug 2020
- Expected to finish
-
Aug 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adult patients (\>/= 18 years) who have biopsy proven indeterminate thyroid nodules (Bethesda III only) that have been molecular profiled benign, who refuse to undergo or are not good candidates for surgical resection
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Indeterminate Bethesda III nodules that have been molecularly profiled benign with either Afirma Genomic Sequencing Classifier (GSC) or ThyroSeq v3 tests Exclusion Criteria: * cardiac arrthymias * pregnancy
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Indeterminate bethesda iii thyroid nodules are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Columbia University
RECRUITINGNew York, New York, 10032, United States